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Proteasome activityN-a-acetyltransferase 10 protein (Naa10p) regulates various pathways associated with cancer cell
proliferation, metastasis, apoptosis and autophagy. However, its role in protein quality control is
unknown. Here, we report that Naa10p is physically associated with proteasome activator 28b
(PA28b). Naa10p also interacts with PA28a in a PA28b-dependent manner. Naa10p negatively regu-
lates PA28-dependent chymotrypsin-like proteasome activity in cancer cells and in a cell-free sys-
tem reconstituted with puriﬁed proteins, which is not related to 26S proteasome.
Acetyltransferase activity of Naa10p is not required for its effect on chymotrypsin-like proteasome
activity. Therefore, our data reveal that Naa10p suppresses 28S proteasome activity through interac-
tion with PA28b.
Structured summary of protein interactions:
Naa10p physically interacts with PA28 alpha and PA28 beta by anti bait coimmunoprecipitation (View
Interaction: 1, 2)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction genesis [5–7,10–12,17], despite that the precise role of Naa10pN-a-acetyltransferase 10 protein (Naa10p, also known as ARD1)
is the catalytic subunit of N-acetyltransferase A (NatA), one of ma-
jor N-terminal acetyltransferase complexes in eukaryotes [1].
Naa10p catalyzes N-a-acetylation of nascent polypeptides emerg-
ing from ribosomes [2–4], lysine e-acetylation of mature proteins
[5], lysine autoacetylation [6], and acts as a transcriptional co-fac-
tor [7]. By synergizing with diverse signaling proteins, Naa10p has
been implicated in controlling cell proliferation [5,6], apoptosis
[8,9], metastasis [10], autophagy [11], hypoxic signaling [12], and
neuronal development [13,14]. Recently, overexpression and prog-
nostic value of Naa10p had been validated in several types of can-
cer [7,10,15,16] and more than one potential mechanism was
proposed to explain the association between Naa10p and carcino-may differ in distinct cancer types [18].
Proteasomes play a fundamental role in protein turnover and
therefore are essential for different cellular functions, including tu-
mor development and response to anti-cancer agents [19–21]. It is
also responsible for the proteolytic maturation of diverse polypep-
tide precursors and for the degradation of cell regulators, whose
destruction is necessary for progression through such cellular
events as cell cycle (e.g. b-catenin and cyclins) [22], cell death (e.g.
p53 and NFjB) [23], cell division, differentiation, and adaptation
to environmental stresses [24]. Generally, most of these functions
are conducted by 26S proteasome, which is formed by a 20S
proteasome core plus one or two 19S proteasome activator [19].
The proteasome activator is essential for the access of target
proteins to 20S core. Besides the well-studied 19S activator, other
forms of proteasome activator were also characterized. 11S activa-
tor (proteasome activator 28, a heteroheptamer consisting of
PA28a and PA28b), for example, can only stimulate the hydrolysis
of model peptide substrates but not proteins in an ATP-indepen-
dent manner [25,26]. It was reported to activate proteasomes to
generate the antigenic peptides presented by MHC class I mole-
cules, owning to the ATP-independent peptide processing ability
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teasome remains obscure.
In this present study, PA28b was revealed as a novel binding
protein of Naa10p and the consequential biological effect
was investigated, which offers a new insight into the role of
Naa10p.
2. Materials and methods
2.1. Antibodies and reagents
Anti-Naa10p monoclonal antibodies (14D4 for Western blot
analysis, 4D10 and 10C12 for immunoprecipitation assay) were
characterized in our previous studies [15]. Anti-PA28b and anti-
PA28a antibodies were purchased from Cell Signaling Technology
(Beverly, MA). Anti-V5 tag antibody was purchased from Abcam
(Cambridge, MA). Rabbit anti-Myc tag (AB103) and anti-GST tag
(AB101) were from TianGen Biotech (Beijing, China). Recombinant
human PA28a/b complex was purchased from Sigma–Aldrich (St.
Louis, MO). Recombinant human 20S proteasome was purchased
from Enzo (France). 26S Proteasome Fraction was purchased from
GeneTex (San Antonio, TX). GST-Naa10p and GST protein were ex-
pressed using pGEX-5X3 vector by Escherichia coli strain JM109 and
puriﬁed. Proteasome-Glo™ Chymotrypsin-Like Assay Kit was pur-
chased from Promega (Madison, WI).
2.2. Cell culture and transfection
Colon cancer cell line RKO, lung cancer cell lines H1299 and PG
were purchased from American Type Culture Collection (ATCC) and
maintained in standard culture conditions. Stable shNaa10p-
silencing cell lines generated with RKO cells and H1299 cells were
described in our previous papers [8,15,16]. Plasmids encoding V5-
tagged wild-type Naa10p and mutant (R82A) Naa10p were kindly
provided by Dr. Li-Jung Juan and Dr. Shih-Huan Peng (Genomics
Research Center, Academia Sinica, Taipei, Taiwan). Targeted se-
quence for short hairpin RNA (shRNA)-induced silencing of Naa10p
was 50-CCCUGCACCUCUAUUCCAA-30, using psilencer2.1-U6/neoFig. 1. Ligand peptide library screening suggested Naa10p interacts with PA28b. (A) Pha
Microtiter wells were coated with 5 lg/ml GST-Naa10p or with GST as negative control, t
were detected by incubation with HRP-conjugated anti-M13 antibody. The values shown
Pull-down assay of Naa10p and X12 peptide interaction. GST, GST-X12 peptide and huma
of the docked complex of Naa10p-X12. X12 is represented by stick and ball model and t
X12 peptide and PA28b.plasmid. Control shRNA sequence was 50-UUCUCCGAACGUGUCAC-
GU-30. PA28a-speciﬁc siRNA sequence was 50-AAGCCAAGGTG-
GATGTGTT-30. PA28b-speciﬁc siRNA sequence was 50-CGUCAA
GACCAAAGUGGAA-30. Control siRNA sequence was 50-UUCUCC-
GAACGUGUCACGU-30. Transfection was performed with Lipofect-
amine 2000 (Invitrogen, Carlsbad, CA).
2.3. Cell-based proteasome activity assay
RKO cells were cultured in 96-well plate at a density of 1  104
cells per well with 100 ll RPMI 1640 medium (Hyclone, Logan, UT),
supplemented with 10% fetal calf serum (Invitrogen). 12 h later,
the proteasome activity was determined using the Proteasome-
Glo™ Chymotrypsin-Like Cell-Based Assay kit according to the
manufacturer’s protocol. The luminescent intensity was measured
by Lmax II luminometer (Agilent, Santa Clara, CA).
2.4. In vitro proteasome activity assay
Human 20S proteasomes (0.5 lg) or 26S proteasome fraction
(0.25 lg) were assayed in a reaction buffer containing 20 mM
Tris–HCl (pH 7.5), 5 mM Mg2 +, 1 mM DTT. 28S activator
(0.75 lg), GST-Naa10p (0.4 lg), and GST (0.2 lg) protein were
added selectively according to groups for proteasome assays. Reac-
tion was performed at 30 C for 2 min, then the proteasome activ-
ity was detected using the Proteasome-Glo™ Chymotrypsin-Like
Cell-Based Assay kit. Fluorescence was measured every 2 min for
1 h.2.5. Homology modeling of Naa10p
The tertiary structure of Naa10p was built by homology model-
ing with Drug Discovery studioTM 2.5 software package (Accelrys
Inc., San Diego, CA). The 3D model of Naa10p was generated by
MODELLER developed by Sali et al. [28], which performs auto-
mated protein homology modeling and loop modeling for Naa10p.
Then the quality of 3D model of Naa10p was evaluated by a seriesge ELISA was used to screen the phage clones that speciﬁcally bound with Naa10p.
hen blocked with 5% skim milk. Phage clones was added to the wells. Bound phages
are the mean OD492 of triplicate samples. S.D. are indicated by error bars. (B) GST
n recombinant His-Naa10p were puriﬁed from E. coli. (C) Top scoring conformation
he surface of Naa10p are shown by green color. (D) A Sequence homology between
1632 L. Min et al. / FEBS Letters 587 (2013) 1630–1637of tests for internal consistency and reliability including Raman-
chandran Plot and Proﬁle 3D.
2.6. Molecular dynamic simulation and in silicon interaction study
3D structure of X12 was simulated by CHARMm in DS modeling
which provides powerful mechanics and dynamics protocols for
studying the energetic and motion of molecules [29]. Accelrys
CHARMm forceﬁeld was used throughout the simulation. The ob-
tained optimized structure of X12 was used for the following
docking.
Docked conformation and interaction energies were obtained
using the docking program ZDOCK [30]. The free energies were cal-
culated based on shape complementarity as type of correlation
using a default grid spacing of 2.0 Å. The highest-ranked 2000 de-
coys were clustered based on structural similarity among the pre-
dicted docking forms. The features of generated clusters were
analyzed to estimate the biological relevance of Naa10p and X12
interactions. 10 top-scored docked conformations were retained
for further optimization using docking program RDOCK. The bind-
ing interfaces of reﬁned docked complexes were analyzed.
2.7. Immunoprecipitation, Western blot, and GST pull-down assay
Immunoprecipitation and Western blot were performed as pre-
viously reported [8]. To generate the GST-X12 fusion protein, the
sense and the antisense oligonucleotide fragments encoding the
X12 peptide were inserted into the BamH I and Sal I-digested
pGEX-4T-1 vector. Recombinant GST-X12, GST and His-Naa10p
proteins were separately expressed in E. coli and puriﬁed. For
Fig. 1B 1 lg His-Naa10p was incubated with 1 lg of either GST-
X12 or GST plus GSH beads in binding buffer (50 mM Hepes pH
7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF,
1 mM DTT, 10% glycerol) at 4 C overnight, followed by washing
with the same binding buffer for three times. Proteins were re-
solved by SDS–PAGE and subjected to Western blot with anti-
Naa10p antibody or anti-GST antibody. Alternatively, pull-down
assay was performed by incubating 1 mg lysate of RKO cells over-
expressing Myc-PA28b (Fig. 2B) or 1 lg of recombinant His-PA28b
(Fig. 2C) with 1 lg of either recombinant GST-Naa10p or GST plus
GSH beads.
2.8. Statistical analysis
Results are expressed as mean ± standard error (represented as
error bars) from at least three experiments. P values were calcu-
lated by performing the two-tailed Student’s t-test and P < 0.05
was considered statistically signiﬁcant.3. Results
3.1. Ligand peptide library screening suggested Naa10p–PA28b
interaction
To gain an insight into the biological role of Naa10p, phage-dis-
played peptide library was applied to ﬁnd the motif sequence of
Naa10p-interacting proteins with GST-Naa10p as bait (detail
method shown in Supplementary information). Five positive
clones signiﬁcantly higher than the background in ELISA assay
were picked up after three rounds of panning (Fig. 1A), and all
the ﬁve clones had an identical sequence, (NH2)-
WDLWDFYAEAAV, named X12. To verify the interaction between
Naa10p with X12, GST pull-down assay was performed with re-
combinant proteins. The data suggested that the GST-X12 fusion
protein directly interacted with His-Naa10p (Fig. 1B).To further investigate the dynamic characteristics of this inter-
action, we conducted protein docking analysis of Naa10p and X12
peptide. Since the sequence identity of 2X7B to Naa10p is 37%
(Fig. S1A), the crystal structure of 2X7B (available from PDB) was
used as the template for homology modeling of Naa10p (ribbon
representation of the 3D model of Naa10p was shown in
Fig. S1B). Ramanchandran Plot and ZDOCK were performed succes-
sively, to get top scoring conformations, which show the best inter-
action tendency with the lowest free energy of the docked complex
(detail description and parameters seen in Supplementary infor-
mation). Docked conformations were retained for further optimi-
zation using docking program RDOCK and the best scored
conformation of reﬁned docked complex of Naa10p-X12 was
shown in Fig. 1C. Then identiﬁcation of binding interface was per-
formed to get the best scored conformations using a grid spacing of
2.0 Å, and residues of X12 dedicated to hydrogen bonds were
shown in Fig. S1C, indicating the key residues of X12 involved in
the relevant interactions are Asp2, Leu3, Asp5, and Tyr7. Binding
interface of Naa10p includes Arg82, Arg83, Leu84, Gly85, Leu86,
Gln88, Asp92, and Tyr122, which could also be critical for the
X12-Naa10p interaction.
Based on these key residues and BLAST homology search, we
found that X12 had signiﬁcant homology to the residues 208–
215 (DLRAFYAE) of PA28b by BLAST homology search, especially
at these key residues (Fig. 1D).
3.2. Naa10p interacts with PA28b–PA28a complex
To investigate the potential interaction between Naa10p and
PA28b, we performed co-immunoprecipitation assays. Our results
indicated that endogenous Naa10p was able to associate with
Myc-tagged PA28b overexpressed in RKO cells (Fig. 2A). GST pull-
down assay with recombinant GST-Naa10p and lysate from cells
expressing Myc-PA28b also veriﬁed an association between
Naa10p and PA28b (Fig. 2B). Moreover, we found that bacterially
expressed recombinant His-tagged PA28b was able to bind with
puriﬁed GST-Naa10p protein (Fig. 2C), indicating Naa10p interacts
with PA28b directly.
In agreement with these data, immunoprecipitation was used
to detect the interaction between endogenous Naa10p and PA28b
in both RKO cells (Fig. 2D) and PG cells (Fig. S1D). We found that
endogenous Naa10p associates with PA28b as well as PA28a
(Fig. 2D and Fig. S1D). Although PA28b always complexes with
PA28a and they are 48% conserved at protein level [19,31], we pre-
dicted that PA28a–Naa10p interaction may be indirect because
PA28a has no DLRAFYAE motif (Fig. S1E). To verify this notion,
PA28b was knocked down by siRNA in RKO cells. Silencing of
PA28b had no effect on the protein level of Naa10p or PA28a,
but PA28a could no longer be precipitated by anti-Naa10p anti-
body (Fig. 2E). However, PA28b–Naa10p interaction was not ef-
fected by PA28a silencing (Fig. 2F). These results indicated that
the interaction between Naa10p and PA28b is direct and the bind-
ing of PA28a with Naa10p is PA28b-dependent.
3.3. Naa10p inhibits PA28-activated chymotrypsin-like proteasome
activity in vivo and in vitro
Since PA28b and PA28a form a heteroheptamer to stimulate the
hydrolysis of model peptide substrates in 20S core of the 28S pro-
teasome [19], it is tempting to speculate that Naa10p may affect
the activity of 28S proteasome through its interaction with
PA28b. To verify this hypothesis, RKO cells stably transfected with
shNaa10p were used to detect chymotrypsin-like proteasome
activity, a typical PA28-activated proteasome function. As shown
in Fig. 3A, the activity was up-regulated in Naa10p-silenced RKO
cells. Similar results were observed in Naa10p-silenced H1299 cells
Fig. 2. Naa10p directly interacts with PA28b independent of PA28a. (A) The interaction between endogenous Naa10p and exogenous Myc-tagged PA28b in RKO cells.
Coimmunoprecipitation assays was performed with anti-Naa10p antibody to pull-down proteins from lysate of RKO cells overexpressing Myc-PA28b. LC, IgG light chain. HC,
IgG heavy chain. (B) GST pull-down assays using recombinant GST-Naa10p. RKO cell lysate was used as the source of exogenous Myc-PA28b. GST served as negative control.
(C) GST pull-down assays, using recombinant GST-Naa10p and His-PA28b. (D) The interaction between endogenous Naa10p, PA28b and PA28a. Anti-Naa10p antibody was
applied to precipitate proteins from lysate of RKO cells. (E) The interaction between endogenous Naa10p and PA28a upon PA28b silencing. (F) The interaction between
endogenous Naa10p and PA28b upon PA28a silencing. Anti-Naa10p antibody was applied to precipitate proteins from lysate of RKO cells. IgG served as a negative control.
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Fig. 3. Naa10p inhibits PA28-activated chymotrypsin-like proteasome activity in vivo and in vitro. (A, B and C) Naa10p inhibits PA28-activated chymotrypsin-like
proteasome activity in vivo. RKO (A) and H1299 (B) cells were stably transfected with shNaa10p, and RKO (C) cells were transiently transfected with pcDNA3.1-V5-Naa10p
and pcDNA3.1 (control). Upper panels showed Western blot analysis of Naa10p protein levels, b-Actin served as loading control. Lower panels displayed chymotrypsin-like
proteasome activity of these cells in duplicates. P values were determined by Student’s t-test. (D) RKO cells were co-transfected with pcDNA3.1-V5-Naa10p and pCMV-Myc-
PA28b, plus their respective control vectors. Protein levels of V5-Naa10p, Myc-PA28b and b-Actin were detected by Western blot. The chymotrypsin-like proteasome activity
of each group was measured in triplicate. P values were determined by Student’s t-test. (E) Naa10p inhibits PA28-activated chymotrypsin-like proteasome activity in vitro. A
cell-free system consisting of puriﬁed proteins was established to validate effect of Naa10p on 28S proteasomes. Each group was tested in triplicates. Different groups were
discriminated by color. (F) Naa10p has no effect on chymotrypsin-like proteasome activity of 26S proteasomes.
1634 L. Min et al. / FEBS Letters 587 (2013) 1630–1637
Fig. 4. Naa10p deregulates PA28-activated chymotrypsin-like proteasome activity independent of its acetyltransferase activity. RKO cells were transfected with pcDNA3.1
vector, pcDNA3.1-V5-Naa10p, and pcDNA3.1-V5-Naa10p-R82A respectively. (A) Upper panel showed Western blot analysis of Naa10p protein level. b-Actin served as loading
control. Lower panel displayed cell-based chymotrypsin-like proteasome activity in triplicates. (B) Immunoprecipitation assays, using anti-V5 antibody, were applied to
enrich exogenous V5-Naa10p and V5-Naa10p-R82A. Upper panel showed Western blot of the immunoprecipitated proteins. Lower panel displayed their effect on
chymotrypsin-like proteasome activity in an in vitro system. P values were determined by Student’s t-test.
L. Min et al. / FEBS Letters 587 (2013) 1630–1637 1635(Fig. 3B). In contrast, RKO cells overexpressing V5-tagged Naa10p
exhibited lowered chymotrypsin-like proteasome activity com-
pared with the control cells (Fig. 3C). Therefore, Naa10p functions
as a negative regulator of 28S proteasome activity in cells. Protein
levels of PA28a and PA28bwere also evaluated to rule out the pos-
sibility that Naa10p may inﬂuence proteasome activity by altering
the expression of PA28 components (Fig. 3A–C). Moreover, we co-
transfected RKO cells with PA28b and Naa10p (Fig. 3D). The data
demonstrated that exogenous PA28b signiﬁcantly upregulated
chymotrypsin-like proteasome activity, which was diminished by
co-transfection of Naa10p (Fig. 3D), suggesting that PA28b and
Naa10p regulated chymotrypsin-like proteasome activity simulta-
neously, not mutually exclusively. Next, we established a cell-free
system consisting of puriﬁed proteins to further validate the inﬂu-
ence of Naa10p on 28S proteasome activity. In agreement with the
previous ﬁndings [31], 28S activator upregulated chymotrypsin-
like proteasome activity of 20S proteasome core, and this activa-
tion was interfered by GST-Naa10p protein (Fig. 3E). However,
GST-Naa10p protein has no effect on 20S proteasome core in the
absence of 28S activator (Fig. 3E), indicating the effect of Naa10p
on chymotrypsin-like proteasome activity was PA28-dependent.
Additionally, we found Naa10p had no effect on chymotrypsin-like
proteasome activity of 26S proteasome in the same in vitro system
(Fig. 3F).
3.4. Acetyltransferase activity of Naa10p is not necessary for inhibiting
chymotrypsin-like proteasome activity
To investigate the potential contribution of Naa10p’s acetyl-
transferase activity in regulating chymotrypsin-like proteasome
activity, we used a V5-tagged mutant Naa10p construct (R82A,namely Ala was substituted for Arg82), which had lost its ability
to bind with acetyl-CoA, thus exhibiting defective acetyltransferase
activity as characterized by previous studies [6,7]. RKO cells trans-
fected with V5-tagged wild-type Naa10p and Naa10p-R82A inhib-
ited chymotrypsin-like proteasome activity to a similar extend
(Fig. 4A). Same conclusion was obtained by using cell-free system
using immunoprecipitated wild-type Naa10p and Naa10p-R82A
(Fig. 4B). Thus, Naa10p negatively regulates PA28-activated chy-
motrypsin-like proteasome activity in an acetylation-independent
manner.4. Discussion
Chymotrypsin-like proteasome activity is a representative func-
tion of 20S core proteasomes, which can be activated by PA28a/b
complex [19,26]. It was reported that 20S proteasome’s catalytic
subunit could be inactivated by NatA in yeast [22], but association
between proteasome and N-a-acetyltransferase is largely elusive.
Our study presents a potential regulatory mechanism between
PA28 complex and acetyltransferase Naa10p in human cells.
We revealed that Naa10p interacted with both exogenous and
endogenous PA28b. The result that PA28a can also interact with
Naa10p strongly argues that PA28 complex may interact with
Naa10p as a whole, since a subunits and b subunits never being
found alone in cells [19]. However, probably due to lacking of
DLRAFYAE motif, PA28a’s interaction with Naa10p is mediated
by PA28b.
Our data also demonstrated that Naa10p negatively regulated
chymotrypsin-like proteasome activity in cells. Consistent with
these, in a cell-free system consisting of puriﬁed 20S core protea-
1636 L. Min et al. / FEBS Letters 587 (2013) 1630–1637somes and 28S activator complexes, GST-Naa10p could also com-
promise the speed of substrate peptides degradation. However,
Naa10p alone had no effect on chymotrypsin-like proteasome
activity of 20S core proteasome in the absence of PA28 complex.
Together, PA28b-dependent inhibition of Naa10p on chymotryp-
sin-like proteasome activity partially explains the biological rele-
vance of the interaction between Naa10p and PA28b.
Although Naa10p is an acetyltransferase, there are indications
that it also mediates non-catalytic functions [7,10]. In this study,
we used enzyme-dead mutant Naa10p to check the contribution
of acetyltransferase activity to the regulation of proteasome activ-
ity. Results showed that mutant and wild-type Naa10p had similar
inhibitory effect on chymotrypsin-like proteasome activity in vivo
and in vitro, suggesting that acetyltransferase activity is not re-
quired for such regulation. As PA28a/b complex always exhibits
a lid-like structure on the ends of 20S core proteasomes, it is pos-
sible that binding with Naa10p, a protein of 26.5 kD, may bring ste-
ric hindrance for peptides entry. However, this speculation still
needs further investigation.
It was thought that PA28a/b complexes have a role of activat-
ing proteasomes to generate the antigenic peptides presented by
MHC class I molecules [27,32]. Therefore, interfering effect of
Naa10p on PA28-regulated chymotrypsin-like proteasome activ-
ity might impair tumor antigenic peptides presentation, or shift
the repertoire of tumor-associated antigens presented by MHC
class I, which may result in cells escaping from immunosurveil-
lance and malignant transformation. In addition, Naa10p regu-
lates pathways associated with cell proliferation [5,6],
apoptosis [8,9], metastasis [10], and autophagy [11]. Whether
or not there is any functional association between these path-
ways and PA28-regulated chymotrypsin-like proteasome activity
still needs more considerations.
It was reported that overexpression of Naa10p may serve as a
prognostic factor in different cancers [7,10,15,16,33]. Overexpres-
sion of PA28b was found in gastric adenocarcinomas, though its
prognostic value still needs exploration [34,35]. The proteasome
activity increases in several human diseases, especially cancer
[36], but there are no reports about the chymotrypsin-like pro-
teasome activity in cancer. We believe that the potential rela-
tionship between Naa10p and PA28b may be helpful for better
understanding the role of de-regulated proteasome activity in
carcinogenesis.
In summary, we identiﬁed Naa10p as a novel suppressor of 28S
proteasome through direct interaction with PA28b, which proposes
a new mechanistic insight into the role of Naa10p.
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